# A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)

> **NCT00311740** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 582 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Valsartan
- **DRUG:** Hydrochlorothiazide

## Key facts

- **NCT ID:** NCT00311740
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** 582 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00311740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00311740, "A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00311740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*